Trump signs order to speed review of psychedelics, including the controversial drug ibogaine
Summary
President Donald Trump signed an executive order to speed up the review of certain psychedelic drugs, including ibogaine, to explore their medical use for conditions like severe depression and addiction. The order aims to ease restrictions and promote faster access to potential treatments, with support from health officials and veterans.Key Facts
- President Trump signed the order on April 18, 2026, at the White House.
- Ibogaine and some other psychedelics are currently banned under the strictest federal drug category.
- The executive order directs the government to accelerate research and review of these drugs for medical purposes.
- Psychedelic drugs are being studied for hard-to-treat conditions like post-traumatic stress disorder (PTSD) and opioid addiction.
- Health Secretary Robert F. Kennedy Jr. and other officials support easing access to these drugs.
- The FDA will issue priority review vouchers to shorten approval times for some psychedelics, cutting months of waiting to weeks.
- Conservative podcaster Joe Rogan and retired Navy SEAL Marcus Luttrell attended the signing ceremony and voiced support for the policy.
- The move has bipartisan backing and reflects growing interest in psychedelics' potential medical benefits.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
